Background/Aims: ADAMTSs (A disintegrin and metalloprotease domains with thrombospondins motifs) are a family of extracellular proteases that have been related to both oncogenic and tumor-suppressive functions. The aim of the present study was to investigate: 1) the mutation, copy-number alterations, and expression profile of ADAMTSs in colorectal cancer and 2) whether ADAMTSs participate in colorectal cancer (CRC) progression and invasion. Methods: The mutation, copy-number alterations, and expression profile of ADAMTSs in CRC were analyzed in the TCGA cohort using cBioportal. ADAMTS4 expression in tumor tissues and cell lines were determined by immunostaining and real-time quantitative PCR. The role of ADAMTS-4 in CRC progression and the underlying mechanisms were studied by using short hairpin RNA-mediated knockdown of ADAMTS4. The effects of ADAMTS4 in cell proliferation and invasion were determined by clone formation assay and transwell migration assay, respectively. Macrophages were depleted by liposomal clodronate in immune-competent BALB/c mice and tumor growth was analyzed. Results: ADAMTS4 was differentially expressed in CRC and predicted a poor prognosis. Elevated ADAMTS4 expression was closely associated with larger tumor size, enhanced TNM stage, and a poor clinical outcome in patients with CRC. ADAMTS4 knockdown had no inhibitory implications on cell proliferation and invasion in vitro, but significantly attenuated tumor growth in vivo. Mechanistically, we revealed that ADAMTS4 was associated macrophages infiltration and polarization in the tumor microenvironment of CRC. Macrophage depletion largely abolished the promotive effect of ADAMTS4 on tumor growth in the immune competent BALB/c mice. Conclusion: ADAMTS4 seemed to be a promising prognostic indicator in CRC. The novel link between ADAMTS4 and macrophages mirrors the potential regulatory roles of ADAMTSs in the inflammatory microenvironment of cancers.
Introduction
Colorectal cancer (CRC) is the most common cause of cancer-related deaths worldwide. More than 1.2 million new cases of CRC occur every year globally, accounting for 10% of all cancer cases [1] . Due to early screening and improved treatment, the mortality rates of CRC are decreasing [2] . Despite the incidence of CRC, in developed countries, is stabilized and even declined, there is still the necessity for achieving better understanding tumor biology with a view to develop novel therapeutic strategies.
Extracellular matrix (ECM) components are critically involved in the malignant phenotypes of cancers, especially metastatic events [3] . Specifically, protease-induced breakdown of the ECM components is essential for tumor cells to across tissue barriers [4, 5] . ADAMTS (a disintegrin-like and metalloproteinase with thrombospondin motifs) is a family of extracellular metalloproteinases which was first identified in 1997. To date, 19 ADAMTS family members have been identified. Most of ADAMTSs include the following domain structure from the N-terminus to C-terminal: 1) a signal peptide directs ADAMTS to the secretory pathway; 2) a prodomain maintains enzyme latency; 3) a zinc binding metalloproteinase domain; 4) a disintegrin-like domain; 5) a central Thrombospondin Type 1 repeat (TSR); 6) a cysteine rich domain; 7) a spacer domain; 8) variable number of TSRs [6, 7] . ADAMTSs are involved in diverse functions including matrix degradation, collagen maturation, blood coagulation, organogenesis, and inflammation [8, 9] . However, the functions, mechanisms of activation, and substrates of most ADAMTS members remain largely unexplored [10] . In cancers, ADAMTSs can play both oncogenic and tumor-protective roles through regulating matrix-degradation, angiogenesis and metastasis [8, [11] [12] [13] [14] [15] [16] . Moreover, ADAMTSs mutation is significantly associated with improved chemotherapy sensitivity and progression-free survival in ovarian cancer [17] . Therefore, exploring the roles of ADAMTSs in cancers might provide promising oncotherapeutic options.
In this study, we firstly studied on the mutation, copy-number alterations, and expression profile of ADAMTSs in CRC. The differentially expressed ADAMTS4 was selected for further study including correlation with clinicopathological factors, prognostic value, in vitro and in vivo functions, and related mechanisms. As a result, we demonstrated that overexpressed ADAMTS4 predicted a poor prognosis and contributed to tumor growth by modulating macrophages in CRC.
Materials and Methods

Cell Culture
Five human CRC cell lines (LOVO, SW620, SW480, Caco-2, and HCT15) and a mouse tumor cell line CT26 were all obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences in Shanghai, China. The normal colonic epithelial cell line NCM460 was purchased from American Type Culture Collection (Manassas, VA, ATCC). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) or Roswell Park Memorial Institute (RPMI)-1640 containing 10% fetal bovine serum (FBS) containing 10% fetal bovine serum (FBS). All cells were cultured in a humidified atmosphere containing 5% CO 2 at 37°C.
Data mining
The analyzed TCGA data of colorectal adenocarcinoma (COAD) was downloaded from Broad Institute TCGA Genome Data Analysis Center (https://cancergenome.nih.gov). The expression level of ADAMTS family members was quantified as RSEM (RNA-Seq by expectation-maximization) logarithmically transformed (base 2) in order to follow a normal distribution. The R2 database (http://hgserver1.amc.nl) was used to analyze ADAMTS4-associated genes. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were further used to explore the function of ADAMTS4-associated genes in this database.
Immunohistochemistry
Immunohistochemical analysis was performed as previously described [18] . Information for tissue microarray used in this study was reported previously [19] . Briefly, tissue sections were deparaffinized in 
RNA isolation and quantitative real-time PCR
Total RNA were extracted from the CRC cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and 1 μg RNA was reverse-transcribed into cDNA using PrimerScript RT-PCR kit (Takara, Tokyo, Japan) according to the manufacturer's protocol. Quantitative real time PCR was performed using SYBR green (Applied Biosystems, CA, USA) with a Step One Real-Time PCR system (Applied Biosystems, CA, USA). Gene expression was normalized to GAPDH. Primer sequences are listed as follows: ADAMTS4 forward, 5'-GAGGGAGGCACCCCTAACT-3'; ADAMTS4 reverse, 5'-CCTTGACGTTGCACATGGGA-3'; GAPDH forward, 5'-ACAACTTTGGTATCGTGGAAGG-3'; GAPDH reverse, 5'-GCCATCACGCCACAGTTTC-3'.
Generation of stable cell lines
The short hairpin RNAs targeting ADAMTS4 were designed and purchased from Genepharma (Shanghai, China). The coding sequences of ADAMTS4 were cloned into pCDH-CMV-MCS-EF1-Puro vector (System Biosciences, CA, USA). Virus packaging was performed in 293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Viruses were harvested at 48 h after transfection, and virus titers were determined. Indicated cells (1 × 10 5 ) were infected with 1 × 10 6 recombinant lentivirus-transducing units in the presence of 6 μg/ml polybrene (Sigma-Aldrich, Shanghai, China). The infected cells were screened by 2 μg/ml puromycin (Sangon, Shanghai, China). Puromycin resistant single-cell clones stably expressing ADAMTS4 were established and verified by western blotting analysis.
Western blotting
Total protein was extracted using RIPA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1.0 mM EDTA, 0.1% SDS, and 1% Triton X-100). Protein lysates were separated by a 10% sodium dedecyl sulfate polyacryamide gel (SDS-PAGE) and subsequently transferred onto polyvinylidene difluoride (PVDF) membranes. The blotted membranes were incubated in blocking solution containing 5 % (w/v) non-fat milk powder and 0.1 % (v/v) Tween-20 for 1 h at room temperature. Then the membranes were incubated with the primary antibody of ADAMTS-4 (Abcam, ab84792, diluted at 1:1000) and GAPDH (Abcam, ab8245, diluted at 2:1000) at 4°C overnight, followed by incubation with secondary horseradish peroxidase (HRP)-conjugate anti-rabbit secondary antibody for 1 h at room temperature. Bound antibodies were visualized with the ECL kit (Beyotime, Shanghai, China).
Enzyme linked immunosorbent assay (ELISA)
The ADAMTS4 level was measured from cell culture supernatants by A Human ADAMTS4 DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.
Clone formation assay
The indicated cells (1000 per well) were seeded into six-well plates and cultured for 14 days. The medium was changed every 3 days. Subsequently, formed colonies were fixed with 4% paraformaldehyde (PFA) and then stained with 0.5% crystal violet for 30 min. The number of colonies formed in each well was counted under a microscope.
Cell invasion assay
The invasive potential of Caco-2 and HCT15 cells was monitored by transwell assay (Corning, NY, USA) according to the manufacturer's instructions. Briefly, 2 × 10 4 cells in 100 μl medium were seeded into the upper chamber of matrigel-coated filters (BD Bioscience, San Diego, CA, USA). A total of 700 μl culture medium containing 10 % (v/v) FBS was added to the bottom chamber. After incubation for 48 h, the non-Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry migrated cells that remained on the upper chamber were removed. The migrated cells were fixed with 4% PFA and stained with 0.5% crystal violet. Finally, the number of invaded cells on the lower surface was counted under a light microscope in six random fields.
Animal experiments
For subcutaneous xenograft assay, athymic nude mice (5-week-old) were injected subcutaneously with 2 × 10 6 sh-Ctrl and sh-ADAMTS4 HCT15 cells at the right flank. Tumor size was measured by a slide caliper every 3 days and tumor volume was determined by the formula 0.44 × A × B 2 (A indicates tumor base diameter one direction and B the corresponding perpendicular value). For macrophage depletion assay, BALB/c mice were injected intraperitoneally twice per week with clodronate liposomes (1.4 mg/20 g body weight) or with an equivalent volume of PBS liposomes until week 4. At week 2, BALB/c mice were injected subcutaneously with 2 × 10 6 OV-vector and OV-ADAMTS4 cells at the right flank. Tumor size was monitored every 3 days for 3 weeks. Clodronate liposomes and PBS liposomes were purchased from Dr N Van Rooijen (Vrije Universiteit, Amsterdam, Netherlands). All mice were housed and maintained under specific pathogen-free conditions and used in accordance with institutional guidelines. The animal studies and the process were approved by Ethics Committee of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China.
Flow Cytometry
For detection of tissue macrophages, mice were sacrificed and transcardially perfused with D-Hanks buffer followed by 1mg/ml collagenase type IV (Sigma-Aldrich, Shanghai, China). Cellular suspensions were prepared as follows: isolated tissues were washed in D-Hanks buffer, injected with 5 ml collagenase solution, minced, and digested at 37°C for 30 min. Cells were collected by passing through a 70 μm strainer. Subsequently, single-cell suspensions were blocked with CD16/CD32 antibody (BD Biosciences, CA, USA) and subsequently labeled with antibodies against CD11b (Miltenyi Biotec, Shanghai, China) and Gr1 (AbD Serotec, Oxford, UK) for 30 minutes at 4°C. Finally, stained cells were analyzed by flow cytometry.
Statistical analysis
Data were presented as the means ± SD. Statistical analyses were performed using the SPSS 16.0 software (SPSS, Chicago, IL, USA) and graphical representations were performed with GraphPad Prism 5 (San Diego, CA, USA) software. Correlation of ADAMTS4 expression with clinicopathologic parameters was analyzed by Pearson chi-square test. Overall survival rate was calculated according to the Kaplan-Meier method and the difference in survival curves was evaluated by the log-rank test. Independent prognostic factors were analyzed by the Cox proportional hazards regression model. Paired data were analyzed by Student's t test, and group data were analyzed by one-way analysis of variance (ANOVA). P values less than 0.05 were considered statistically significant.
Results
Differentially expressed ADAMTS4 predicts a poor prognosis in CRC
Emerging evidence has demonstrated that ADAMTS are deregulated in human cancer and implicated in tumor progression [8, 13] . Meanwhile, somatic mutations of ADAMTS genes are associated with chemotherapy sensitivity and patients' survival [20, 21] . To gain further insight into the mutation, copy-number alterations, and expression profile of ADAMTS, we examined the TCGA (provisional) cohort by cBioPortal (http://www.cbioportal.org/). As a result, we noticed that ADAMTS family members were rarely mutated in CRC with a highest mutation frequency for ADAMTS12 at only 2.9% (Fig. 1) . The copy-number alterations, including amplification and deep deletion, were also not frequently observed in CRC (Fig. 2) . Next, by data mining the ADAMTS expression in healthy and cancerous colorectal tissues, we found that 1) ADAMTS-1, -2, -4, and -9 were the most abundant ADAMTS in CRC tissues; 2) ADAMTS-1, -8, and -17 were down-regulated in CRC tissues compared with normal tissues; 3) ADAMTS-2, -3, -4, -6, -7, -9, -12, -14, and -18 were significantly over-expressed in CRC tissues (Fig. 3A) . By Kaplan-Meier curve analysis of the differentially expressed ADAMTS, we
found that only ADAMTS-4 and ADAMTS-6 predicted a poor prognosis in CRC patients in TCGA cohort (Fig. 3B) .
From the therapeutic point of view, we focused on the study of ADAMTS4 in CRC due to its expression profile and prognostic value in CRC. To further confirm ADAMTS4 expression at protein level, we carried out immunohistochemical analysis in a tissue microarray containing 345 cases of CRC specimens. Representative ADAMTS4 staining was shown in Fig. 3C . ADAMTS4 protein was highly expressed in 59.1% (204/345) CRC tissues (Table 1) . Furthermore, the correlation between the ADAMTS4 expression and corresponding clinicopathologi cal parameters of the CRC patients was analyzed. As shown in Table 1 , ADAMTS4 protein expression was significantly correlated with tumor size and TNM stage, whereas no significant difference was found in age, gender, tumor location, serum CEA level and histology. To further determine the prognostic effect of ADAMTS4, the overall survival rate of patients with CRC in Ren Ji cohort was analyzed using KaplanMeier survival curves and the log-rank test. As a result, CRC patients with high ADAMTS4 level had a poor overall survival (OS) compared with those with a lower ADAMTS4 protein level (Fig. 3D) . By univariate Cox regression analysis, we found that ADAMTS4 expression level, serum CEA level and TNM stage all are significant risk factors for OS (Table 2) . And multivariate Cox regression analysis revealed that only TNM stage is an independent factor in the prediction of OS rate of CRC patients (Table 2) . Collectively, these results indicated that over-expressed ADAMTS4 seemed to be a prognostic indicator in CRC and might contribute to the development and progression of CRC.
Genetic silencing of ADAMTS4 inhibits tumor growth in vivo but not in vitro
Since ADAMTS4 is associated with malignant activity in clinical specimens, we investigated the oncogenic roles of ADAMTS4 in vitro and in vivo by loss-of-function assay. By real-time qPCR, we found that ADAMTS4 was commonly elevated in CRC cell lines compared (Fig. 4B) . Plate clone formation assay showed that knockdown of ADAMTS4 failed to influence cell proliferation in vitro (Fig. 4C) . Meanwhile, ADAMTS4 knockdown had no implication on the invasive potential of CRC cells as demonstrated by transwell assay (Fig. 4D) . As the tumor promoter or suppressor functions of ADAMTS4 are largely dependent on the extracellular matrix, we further tested the effect of ADAMTS4 in vivo. Expectedly, silencing of ADAMTS4 resulted in a significant retardation in tumor growth (Fig. 4E) . Consistently, the immunoreactivity of the proliferation index, Ki67, was also remarkably reduced in sh-ADAMTS4-1 group compared to the shCtrl group (Fig. 4F) . Taken together, these data above suggested that ADAMTS4 acted as an oncogene in CRC and its oncogenic roles might be dependent on the alteration of tumor microenvironment.
Macrophages mediate the oncogenic role of ADAMTS4 in the tumor growth of CRC
To pursue the mechanism by which ADAMTS4 promoted tumor growth in vivo, we annotated 1358 ADAMTS4-associated genes (selected by R2 software, R > 0.5) by Gene ontology analysis. The result showed that ADAMTS4 was profoundly involved in the cell adhesion, ECM receptor interaction, PI3K/AKT pathway, and etc (Fig. 5A) . Notably, ADAMTS4 also associated with molecules involved in cytokine and chemokine signaling pathway, suggesting that ADAMTS4 might be implicated in inflammatory response (Fig. 6 ). Given that macrophages are the most abundant immune cells in the tumor microenvironment, we hypothesized that whether ADAMTS4 contributes macrophages infiltration in the tumor microenvironment of CRC [22] . To test this hypothesis, we correlated ADAMTS4 expression with the expression of specific macrophages markers. We found that there was a close correlation between ADAMTS4 and CD68, a classical macrophages marker, indicating that ADAMTS4 may be associated macrophages infiltration in CRC (Fig. 5B) . Furthermore, we noticed that ADAMTS4 had a much higher correlation coefficient with the marker of M2 macrophages CD163 than the M1 macrophages marker CD86 (Fig. 5C ), indicating an antiinflammatory response induced by ADAMTS4. To further test that whether macrophages mediates the oncogenic role of ADAMTS4 in CRC, we generated a subcutaneous xenograft derived from ADAMTS4-overexpressing CT26 cells or the control cells in the immunecompetent BALB/c mice (Fig. 5D ). Liposomal clodronate has been widely used as an effective tool to delete macrophages in various in vivo systems. The treatment schedule was shown in Fig. 5E . Treatment of clodronate liposomes was sufficient to deplete the myeloid cells in the spleen and bone marrow as revealed by flow cytometry (Fig. 5F) . By IHC analysis, we found that tumors of ADAMTS4-overexpressing CT26 cells had more macrophages infiltration than that in OV-vector cells and the infiltrated macrophages in the tumor tissues were largely depleted by clodronate liposomes (Fig. 5G) . Indeed, over-expression of ADAMTS4 promoted tumor growth. And macrophages inhibition had no significant inhibitory role in the OVvector tumors, but largely abolished the growth advantage induced by ADAMTS4 (Fig. 5H) . Therefore, these results demonstrated that macrophages were critically involved in the oncogenic functions of ADAMTS4 in CRC.
Discussion
Emerging data have demonstrated the significant role of ADAMTSs in tumor progression. In this study, we reported the overexpression pattern of ADAMTS4 and its prognostic value Based on bioinformatics analysis, we revealed no significant mutation and copy-number alterations of ADAMTSs in CRC. Meanwhile, we for the first time uncovered a novel link between ADAMTS4 and macrophages, which ultimately facilitate tumor progression. Previously, it has been reported that ADAMTS mutations contribute to outcomes in ovarian cancer cases without BRCA1 or BRCA2 mutations and may have important clinical implications. However, by a large-scale data mining, we failed to observe significant mutation frequency of ADAMTSs in CRC. The dysregulated ADAMTSs in cancers can be induced by many factors. For example, IL-6 upregulates ADAMTS-2 in human osteosarcoma cells mediated by JNK pathway [23] . ADAMTS-1, -9, and -18 have been found to be epigenetically silenced in malignant tumors [24] . In this study, no significant copy-number alterations of ADAMTSs were found in CRC. However, multiple ADAMTSs were found to be differentially expressed in CRC. Combined with the clinical follow-ups, we identified the overexpressed ADAMTS4 as a crucial factor in CRC progression. Consistently, the overexpressed prolife of ADAMTS4 has been reported in several cancers including glioblastoma [25] , head and neck cancer [26] , melanoma [27] , and epithelial ovarian cancer [12] . By immunochemical analysis of a CRC tissue microarray, we confirmed that ADAMTS4 expression was elevated in CRC tissues compared to normal tissues and predicted a poor prognosis in CRC. ADAMTS4 and its proteolytic fragments can differentially affect tumor growth and angiogenesis in melanoma [27] . In this study, by loss-of-function study, genetic silencing of ADAMTS4 showed no obvious implications on cell proliferation and invasive capacity of CRC cells with high ADAMTS4 expression, but remarkably suppressed tumor in vivo, indicating the regulatory roles of ADAMTS4 are largely dependent on ECM. Extensive remodeling of the normal ECM in cancers can progress via the degradation of preexisting ECM molecules, such as aggrecan, brevican, and versican [12] . Alterations in the extracellular environment are critical for tumor initiation and progression. Indeed, based on bioinformatic analysis, we found the implication of ADAMTS4 on ECM. Specifically, we also noticed the potential role of ADAMTS4 in the inflammatory network of CRC tumor microenvironment. And we subsequently confirmed a link between ADAMTS4 and macrophages. To the best of our knowledge, our study is the first time to demonstrate this correlation. Macrophages can 
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Cellular Physiology and Biochemistry promote tumor progression by enhancing chronic inflammation, matrix remodeling and angiogenesis. Deletion of macrophages exhibits antitumor effects in several xenograft tumor models [28] . In this study, clodronate liposomes mediated macrophage depletion did not influence tumor growth remarkably in control group, but largely compromised the promotive effect of ADAMTS4 on tumor growth of CRC in an immunocompetent mouse model, suggesting that the oncogenic roles of ADAMTS4 are at least partially dependent on the macrophages infiltrated in the tumor microenvironment. Notably, the clear mechanism by which ADAMTS4 modulates macrophages polarization and infiltration remains further investigation.
Conclusion
In summary, the results presented in the current study provide both bioinformatic and clinicopathological evidence to show the observation that overexpressed ADAMTS4 correlates tumor progression and predicts poor clinical outcome in CRC. Our findings also revealed a regulatory role of ADAMTS4 on macrophages in the CRC tumor microenvironment.
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